Reconstitution of HIV-specific Immunity Against HIV
|ClinicalTrials.gov Identifier: NCT02563509|
Recruitment Status : Completed
First Posted : September 30, 2015
Last Update Posted : June 6, 2019
|Condition or disease||Intervention/treatment||Phase|
|HIV||Biological: HIV-specific CD8 cells||Phase 1|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||30 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||Reconstitution of HIV-specific Immunity Against HIV|
|Actual Study Start Date :||January 2016|
|Actual Primary Completion Date :||June 2017|
|Actual Study Completion Date :||December 2017|
Experimental: HIV-specific CD8 cells
Transfusing HIV-specific CD8 cells 50-100mlonce a week for four times.
Biological: HIV-specific CD8 cells
Based on HAART, receive HIV-specific CD8 cells transfuion.
No Intervention: Regualar therapy
Only receiving Highly active anti-retroviral therapy(HAART).
- The number and function of HIV-specific CD8 cells in patients with HIV [ Time Frame: 6 Months ]The change of differentiation, proliferation, apoptosis, phenotype, etal.
- All adverse events [ Time Frame: 6 Months ]Chills, Fever, Headache, Nausea, Vomiting, Cough, Skin rashes, Anaphylactic shock, Etal.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02563509
|Guangzhou 8th People's Hospital|
|Guangzhou, Guangdong, China, 510060|
|Principal Investigator:||Hui Zhang, doctor||Sun Yat-sen University|